Are You Eligible for Retatrutide? BMI Requirements, Screening & Who Qualifies

7 min read · Published March 26, 2026 · Reviewed by Dr. [Physician Name]

You have read the results. You are interested. Now the question that determines whether any of it matters: do you qualify?

The clinical trials used specific eligibility criteria — and any future prescribing guidelines will follow similar thresholds. Understanding them now helps you evaluate whether GLP-1 treatment is worth pursuing with a physician, whether the medication in question is retatrutide in the future or tirzepatide today.

The BMI Threshold

Based on TRIUMPH trial inclusion criteria and the prescribing labels of approved GLP-1 medications (tirzepatide, semaglutide), the expected eligibility profile is:

Adults with a BMI of 30 or higher (obesity). OR adults with a BMI of 27 or higher with at least one weight-related health condition — type 2 diabetes, hypertension, dyslipidemia, cardiovascular disease, or obstructive sleep apnea.

In the Philippines, where approximately 38.6% of adults aged 20–59 are classified as overweight or obese, the eligible population is large. But BMI alone does not determine candidacy. It is the starting threshold, not the complete picture.

What a Physician Actually Evaluates

A proper medical screening goes well beyond BMI.

Medical history review. Chronic conditions, current medications, previous weight loss treatments (including what has and has not worked), surgical history, and family medical history — particularly thyroid cancer and MEN 2 syndrome.

Contraindication screening. The conditions listed below that rule out GLP-1 treatment entirely.

Lab work (when clinically indicated). Fasting glucose or HbA1c, thyroid function panel, liver function, kidney function, lipid panel. Not every patient requires full labs — your physician determines what is needed based on your history.

Psychological readiness and goal alignment. Are your expectations realistic? Are you prepared for weekly injections and regular follow-up? Are you planning pregnancy in the near future?

Current medication review. GLP-1 drugs interact with some medications — particularly insulin and sulfonylureas (hypoglycemia risk). Your physician evaluates these interactions.

This is not a checklist exercise. It is clinical judgment applied to your individual circumstances. Two people with identical BMIs may receive different recommendations based on everything above.

Who Should NOT Take Retatrutide

These are firm contraindications — conditions that disqualify a person from GLP-1 treatment.

Personal or family history of medullary thyroid carcinoma (MTC). The most critical exclusion. All GLP-1 class drugs carry a boxed warning based on thyroid C-cell tumors in animal studies.

Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).

Pregnancy, planned pregnancy, or breastfeeding. GLP-1 drugs are not studied in pregnant populations.

Type 1 diabetes. GLP-1 drugs are not appropriate for type 1 diabetes management.

Known hypersensitivity to the compound or its components.

History of severe acute pancreatitis. Physicians exercise significant caution here.

Additional caution applies for patients with gastroparesis, significant kidney impairment, or active gallbladder disease.

For the full safety data including the dysesthesia signal, see retatrutide safety and side effects.

The Self-Qualification Trap

Reading eligibility criteria online — including in this article — can create false certainty in either direction. People with BMI 28 may assume they do not qualify when a physician would consider them eligible given their comorbidities. People with BMI 35 may assume they are automatic candidates when a thyroid history disqualifies them.

Self-qualification from an article is not a medical evaluation. The information here helps you understand the general framework. A physician determines whether that framework applies to you specifically.

What If You Qualify but Retatrutide Is Not Available?

If you meet the eligibility criteria for retatrutide, you almost certainly meet the criteria for tirzepatide — the thresholds overlap significantly. Starting treatment now means building the medical history, treatment response data, and physician relationship that will directly inform whether transitioning to retatrutide is appropriate when it eventually becomes available.

For a comparison of expected results, see retatrutide weight loss data by dose and trial.

For the practical dosing protocol, see how retatrutide dose escalation works.

This article is for educational purposes only and does not constitute medical advice. All treatments require evaluation and prescription by a licensed physician. Individual results vary. Kora Health does not guarantee specific outcomes.